Approaches to the management of uncomplicated genital Chlamydia trachomatis infections

References

• Cates W Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex. Transm. Dis. 26, S2—S7 (1999).
   Web of Science ®Google Scholar
• Holmes K, Mardh P-A, Sparling P, et al. (Eds). Sexually Transmitted Diseases. McGraw-Hill Health Professions Division, NY, USA, 391–405 (1999).
   Google Scholar
• Hogan RJ, Mathews SA, Mukhopadhyay S, Summersgill JT, Timms P. Chlamydial persistence: beyond the biphasic paradigm. Infect. Immun. 72(4), 1843–1855 (2004).
   PubMed Web of Science ®Google Scholar
• •Updated review on chlamydial persistence, focussing on insights into the molecular basis of persistence.
   Google Scholar
• Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbial Rev. 58(4), 686–699 (1994).
   PubMedGoogle Scholar
• Askienazy-Elbhar M, Suchet JH. Persistent 'silent' Chlamydia trachomatis female genital tract infections. Infect. Dis. Obstet. Gynecol 7, 31–34 (1999).
   Google Scholar
• Dean D, Suchland RJ, Stamm WE. Evidence of long-term cervical persistence of C trachomatis by omp 1 genotyping. J. Infect. Dis. 182,909–916 (2000).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2002. Morb. Mortal Wkly Rep. 51,1–80 (2002).
   Google Scholar
• ••Widely accepted guidelines for thetreatment of sexually transmitted diseases (STDs) that were developed in consultation with professionals knowledgeable in the field.
   Google Scholar
• Martin DH, Mroczkowski TF, Dalu ZA, et al A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J. Med. 327,921–925 (1992).
   PubMed Web of Science ®Google Scholar
• Ridgway GL. Treatment of chlamydial genital infection. J. Antimicrob. Chemother. 40(3), 311–314 (1997).
   PubMed Web of Science ®Google Scholar
• Blomer R, Bruch K, Klose U. Ofloxacin in the treatment of gonococcal and chlamydial urethritis. Clin. Ther. 10(3), 263–265 (1988).
   PubMed Web of Science ®Google Scholar
• Hooton TM, Batteiger BE, Judson FN, Spruance SL, Stamm WE. Ofloxacin versus doxycycline for treatment of cervical infection with Chlamydia trachomatis. Antimicrob. Agents. Chemother 36, 1144–1146 (1992).
   PubMed Web of Science ®Google Scholar
• Kitchen VS, Donegan C, Ward H, Thomas B, Harris JR, Taylor-Robinson D. Comparison of ofloxacin with doxycycline in the treatment of nongonococcal urethritis and cervical chlamydial infection. J. Antimicrob. Chemother. 26(Suppl. D), 99–105 (1990).
   Google Scholar
• Mikamo H, Sato Y, Hayasaki Y, Hua YX, Tamaya T Adequate levofloxacin treatment schedules for uterine cervicitis caused by Chlamydia trachomatis. Chemotherapy 46(2), 150–152 (2000).
   PubMed Web of Science ®Google Scholar
• Roblin PM, Hammerschlag MR. In vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae. J. Antimicrob. Chemother. 44(4), 549–551 (1999).
   Google Scholar
• Donati M, Rodriguez Fermepin M, Olmo A, d'Apote L, Cevenini R Comparative in vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. J. Antimicrob. Chemother. 43(6), 825–827 (1999).
   Google Scholar
• Perea EJ, Aznar J, Garcia-Iglesias MC, Pascual A. Comparative in vitro activity of sparfloxacin against genital pathogens. J. Antimicrob. Chemother. 37(Suppl. A), 19–25 (1996).
   Google Scholar
• Phillips I, Dimian C, Barlow D, et al. A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of nongonococcal urethritis in men. J. Antimicrob. Chemother. 37(Suppl. A), 123–134 (1996).
   PubMed Web of Science ®Google Scholar
• Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob. Agents. Chemother. 47(2), 636–642 (2003). Provides a basis for standardizing the methodologic approach and interpretation of antimicrobial testing of chlamydia, and is one of the few studies to date assessing the correlation of clinical outcomes in chlamydial infections with results of susceptibility testing.
   Google Scholar
• Physicians' Desk Reference®. Medical Economics Company, Inc., NJ, USA (2004).
   Google Scholar
• Gladue RP, Bright GM, Isaacson RE, Newborg ME In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob. Agents. Chemother. 33(3), 277–282 (1989).
   Google Scholar
• Adair CD, Gunter M, Stovall TG, McElroy G, Veille JC, Ernest JM. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. Obstet. GynecoL 91(2), 165–168 (1998).
   PubMed Web of Science ®Google Scholar
• Wehbeh HA, Ruggeirio RI\4, Shahem S, Lopez G, Ali Y. Single-dose azithromycin for chlamydia in pregnant women. J. Reprod. Med. 43(6), 509–514 (1998).
   PubMed Web of Science ®Google Scholar
• Neu HC, Young LS, Zinner S, Acar JF (Eds). Clinical Practice. Marcel Dekker, NY, USA, 147–154 (1995).
   Google Scholar
• Handsfield HH. Sexually transmitted chlamydial infections, gonorrhea and syphilis. In: New Macrolides, Azalides and Streptogramins. Neu HC, Young LS, Zinner S (Eds). Marcel Dekker, NY, USA, 167–172 (1993).
   Google Scholar
• Murray L, Kelly GL (Eds). Drug Topics Red Book. Thomson Healthcare, CT, USA (2004).
   Google Scholar
• Magid D, Douglas JM Jr, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann. Intern. Med. 124(4), 389–399 (1996).
   Google Scholar
• Haddix AC, Hillis SD, Kassler WJ. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex. Transm. Dis. 22(5),274-280 (1995).
   Google Scholar
• Petitta A, Hart SM, Bailey EM. Economic evaluation of three methods of treating urogenital chlamydial infections in the emergency department. Pharmacotherapy 19(5), 648–654 (1999).
   PubMed Web of Science ®Google Scholar
• Lau C, Qureshi AK. Azithromycin versus doxycyline for genital chlamydial infections. Sex. Transm. Dis. 29(9), 497–459 (2002).
   PubMed Web of Science ®Google Scholar
• Bachman LH, Stephens J, Richey CM, Hook EW. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes. Sex. Transm. Dis. 26(5),272-278 (1999).
   Google Scholar
• Hillis SD, Coles FB, Litchfield B, et al. Doxycycline and azihromycin for prevention of chlamydial persistence or recurrence 1 month after treatment in women. A use-effectiveness study in public health settings. Sex. Transm. Dis. 25,12-13 (1998).
   Google Scholar
• Brookhoff D. Compliance with doxycycline therapy for out-patient treatment of pelvic inflammatory disease. South. Med. J. 87,1088–1091 (1994).
   PubMed Web of Science ®Google Scholar
• Rice RJ, Bhullar V, Mitchell SH, Bullard J, Knapp J. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. Antimicrob. Agents. Chemother. 39,760–762 (1995).
   PubMed Web of Science ®Google Scholar
• Borsum T, Dannevig L, Storvold G, Melby K. Chlamydia trachomatis: in vitro susceptibility of genital and ocular isolates to some quinolones, amoxicillin and azithromycin. Chemotherapy 36(6), 407–415 (1990).
   Google Scholar
• Christensen JJ, Holten-Andersen W, Nielsen PB. Chlamydia trachomatis: in vitro susceptibility to antibiotics singly and in combination. Acta PathoL Microbial. ImmunoL Scand. IN. 94(5), 329–332 (1986).
   Google Scholar
• Turrentine MA, Newton ER. Amoxicillin or erythromycin for the treatment of antenatal chlamydial infection: a meta-analysis. Obstet. GynecoL 86(6), 1021–1025 (1995).
   PubMed Web of Science ®Google Scholar
• Magat AH, Alger LS, Nagey DA, Hatch V, Lovchik JC. Double-blind randomized study comparing amoxicillin and erythromycin for the treatment of Chlamydia trachomatis in pregnancy. Obstet. GynecoL 81(5), 745–749 (1993).
   Google Scholar
• Crombleholme WR, Schachter J, Grossman M, Landers DV, Sweet RL. Amoxicillin therapy for Chlamydia trachomatis in pregnancy. Obstet. GynecoL 75(5), 752–756 (1990).
   Google Scholar
• Segreti J, Kessler HA, Kapell KS, Trenholme GM. In vitro activity of B-lactam drugs and sulbactam against Chlamydia trachomatis. Diagn. Microbial. Infect. Dis. 15(4), 371–373 (1992).
   Google Scholar
• Cross NA, Kellock DJ, Kinghorn GR, et al. Antimicrobial susceptibility testing of Chlamydia trachomatis using a reverse transcriptase PCR-based method. Antimicrob. Agents. Chemother. 43(9), 2311–2313 (1999).
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Manire GP. Electron microscopic observations on the effects of penicillin on the morphology of Chlamydia psittaci. J. Bacterial. 101(1), 278–285 (1970).
   PubMed Web of Science ®Google Scholar
• Kramer MJ, Gordon FB. Ultrastructural analysis of the effects of penicillin and chlortetracycline on the development of a genital tract chlamydia. Infect. Immun. 3, 333–341 (1971).
   PubMed Web of Science ®Google Scholar
• Clark RB, Schatzki PF, Dalton HR Ultrastructural effect of penicillin and cycloheximide on Chlamydia trachomatis strain HAR-13. Med. Microbial. ImmunoL (Berl.) 171(3), 151–159 (1982).
   Google Scholar
• Johnson FW, Hobson D. The effect of penicillin on genital strains of Chlamydia trachomatis in tissue culture. J. Antimicrob. Chemother. 3(1), 49–56 (1977).
   Google Scholar
• Handsfield HH, McCormack WM, Hook EW III, et al. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N EngL J. Med. 325(19), 1337–1341 (1991).
   Google Scholar
• Megran DW, Lefebvre K, Willetts V, Bowie WR. Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men. Antimicrob. Agents. Chemother. 34(2), 355–357 (1990).
   PubMed Web of Science ®Google Scholar
• Schachter J. Rifampin in chlamydial infections. Rev. Infect. Dis. 5\(Suppl. 3), S562—S564 (1983).
   PubMedGoogle Scholar
• Jones RB, Ridgway GL, Boulding S, Hunley KL. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis. Rev. Infect. Dis. 5\(Suppl. 3), S556—S561 (1983).
   Google Scholar
• Cevenini R, Landini MP, Donati M, Rumpianesi E Antimicrobial drug susceptibility of 15 strains of Chlamydia trachomatis recently isolated from cases of nongonococcal urethritis, in Italy. J. Antimicrob. Chemother. 6(2), 294–296 (1980).
   Google Scholar
• Bianchi A, Scieux C, Salmeron CM, Casin I, Perol Y. Rapid determination of MIC values of 15 antichlamydial agents by using an enzyme immunoassay (Chlamydiazyme). Antimicrob. Agents Chemother. 32(9), 1350–1353 (1988).
   PubMed Web of Science ®Google Scholar
• Keshishyan H, Hanna L, Jawefz E. Emergence of rifampin-resistance in Chlamydia trachomatis. Nature 244(5412), 173–174 (1973).
   Google Scholar
• Dreses-Werringloer U, Padubrin I, Kohler L, Hudson AP Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis. Antimicrob. Agents Chemother. 47(7), 2316–2318 (2003).
   Web of Science ®Google Scholar
• Treharne JD, Yearsley PJ, Ballard RC. In vitro studies of Chlamydia trachomatis susceptibility and resistance to rifampin and rifabutin. Antimicrob. Agents Chemother. 33(8), 1393–1394 (1989).
   Google Scholar
• Segreti J, Kessler HA, Kapell KS, Trenholme GM. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. Antimicrob. Agents Chemother. 31(1), 100–101 (1987).
   Google Scholar
• Hammerschlag MR. Activity of trimethoprim—sulfamethoxazole against Chlamydia trachomatis in vitro. Rev. Infect. Dis. 4(2), 500–505 (1982).
   Google Scholar
• Brunham RC, Kuo C, Stevens CE, Holmes KK. Treatment of concomitant Neisseria gonorrhoeae and Chlamydia trachomatis infections in women: comparison of trimethoprim—sulfamethoxazole with ampicillin—probenecid. Rev. Infect. Dis. 4(2), 491–499 (1982).
   Google Scholar
• Bowie WR, Manzon LM, Borrie-Hume CJ, Fawcett A, Jones HD. Efficacy of treatment regimens for lower urogenital Chlamydia trachomatis infection in women. Am. J. Obstet. Gynecol 142(2), 125–129 (1982).
   Web of Science ®Google Scholar
• Paavonen J, Kousa M, Saikku P, Vartiainen E, Kanerva L, Lassus A. Treatment of nongonococcal urethritis with trimethoprim—sulphadiazine and with placebo. A double-blind partner-controlled study. Br. J. Vener. Dis. 56(2), 101–104 (1980).
   PubMedGoogle Scholar
• Alger LS, Lovchik JC. Comparative efficacy of clindamycin versus erythromycin in eradication of antenatal Chlamydia trachomatis. Am. J. Obstet. Gyneco. 165(2), 375–381 (1991).
   Web of Science ®Google Scholar
• Miller JM, Martin DH. Treatment of Chlamydia trachomatis infections in pregnant women. Drugs 60(3), 597–605 (2000).
   Google Scholar
• Campbell WF, Dodson MG. Clindamycin therapy for Chlamydia trachomatis in women. Am. J. Obstet. Gynecol 162(2), 343–347 (1990).
   Google Scholar
• Walsh M, Kappus EW, Quinn TC. In vitro evaluation of CP-62,993, erythromycin, dindamycin, and tetracycline against Chlamydia trachomatis. Antimicrob. Agents Chemother. 31(5), 811–812 (1987).
   Google Scholar
• Harrison HR, Riggin RI\4, Alexander ER, Weinstein L. In vitro activity of dindamycin against strains of Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma urealyticum isolated from pregnant women. Am. J. Obstet. Gynecol 149(5), 477–480 (1984).
   Google Scholar
• Bowie WR. In vitro activity of dindamycin against Chlamydia trachomatis. Sex. Transm. Dis. 8(3), 220–221 (1981).
   Google Scholar
• Gough AW, Kasali OB, Sigler RE, Baragi V. Quinolone arthropathy — acute toxicity to immature cartilage. Toxicol Pathol 20, 436–450 (1992).
   PubMed Web of Science ®Google Scholar
• Morrison RP, Feilzer K, Tumas DB. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect. Immun. 63,4661–4668 (1995).
   PubMed Web of Science ®Google Scholar
• Morrison RP, Caldwell HD. Immunity to murine chlamydial genital infection. Infect. Immun. 70,2741–2751 (2002).
   PubMed Web of Science ®Google Scholar
• Brunham RC, Cohen CR, Kimani J, Bwayo J, Plummer F, and members of the University of Nairobi STI/HIV Study Group. Type 1/Type 2 immunity and Chlamydia trachomatis: insights from the influence of HIV. In: Chlamydial Infections. Proceedings of the 10th International Symposium on Human Chlamydial Infections. Schachter J, Christiansen G, Clark IN, et al. (Eds). International Chlamydia Symposium, CA, USA, 233–236 (2002).
   Google Scholar
• Rompalo AM, Price CB, Roberts PL, Stamm WE. Potential value of rectal-screening cultures for Chlamydia trachomatis in homosexual men. J. Infect. Dis. 153(5), 888–892 (1986).
   Google Scholar
• Lyss SB, Kamb ML, Peterman TA, et al, and the Project RESPECT Study Group. Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States. Ann. Intern. Med. 139(3), 178–185 (2003).
   Google Scholar
• Handsfield HH, Dalu ZA, Martin DH, Douglas JM Jr, McCarty JM, Schlossberg D. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex. Transm. Dis. 21(2), 107–111 (1994).
   PubMed Web of Science ®Google Scholar
• Tapsall JW, Shultz TR, Limnios EA, Donovan B, Lum G, Mulhall BP Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex. Transm. Dis. 25(10), 505–508 (1998).
   PubMed Web of Science ®Google Scholar
• Gruber F, Brajac I, Jonjic A, Grubisic-Greblo H, Lenkovic M, Stasic A. Comparative trial of azithromycin and ciprofloxacin in the treatment of gonorrhea. J. Chemother. 9(4), 263–266 (1997).
   PubMed Web of Science ®Google Scholar
• Habib AR, Fernando R Efficacy of azithromycin lg single dose in the management of uncomplicated gonorrhea. Int. J. STD AIDS 15,240–242 (2004).
   PubMed Web of Science ®Google Scholar
• Whittington WL, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex. Transm. Dis. 28(2), 117–123 (2001).
   Google Scholar
• Rietmeijer CA, Van Bemmelen R, Judson FN, Douglas JM Jr. Incidence and repeat infection rates of Chlamydia trachomatis among male and female patients in an STD clinic: implications for screening and rescreening. Sex. Transm. Dis. 29,65–72 (2002).
   PubMed Web of Science ®Google Scholar
• Hillis SD, Owens LM, Marchbanks PA, Amsterdam LF, MacKenzie WR. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am. J. Obstet. Gynecol 176,103–107 (1997).
   PubMed Web of Science ®Google Scholar
• Ramstedt K, Forssman L, Johannisson G. Contact tracing in the control of genital Chlamydia trachomatis infection. Int. J. STD AIDS 2(2), 116–118 (1991).
   Google Scholar
• Kissinger P, Brown R, Reed K, et al. Effectiveness of patient delivered partner medication for preventing recurrent Chlamydia trachomatis. Sex. Transm. Infect 74(5), 331–333 (1998).
   Google Scholar
• Schillinger JA, Kissinger P, Calvet H, et al Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex. Transm. Dis. 30(1), 49–56 (2003).
   Google Scholar
• Klausner JD, Chaw JK Patient-delivered therapy for chlamydia: putting research into practice. Sex. Transm. Dis. 30(6), 509–511 (2003).
   PubMed Web of Science ®Google Scholar
• ••Details real world experiences with chlamydia-infected patients delivering therapy to their partners in the clinical setting of a municipal STD clinic in San Francisco.
   Google Scholar
• Golden MR, Whittington WLH, Handsfield HH, et al. Impact of sex partner treatment without mandatory prior clinical evaluation on recurrent/persistent gonorrhea or chlamydial infection: a randomized trial. Abstracts of the 2003 International Society for Sexually Transmitted Diseases Research Congress. Ottawa, Canada, 27–30 July 2003 (Abstract 0703).
   Google Scholar
• •• Provides preliminary data from a randomized trial evaluating the impact of expedited partner treatment versus standard partner care for partners of chlamydia or gonorrhea-infected patients on the rate of recurrence/persistence of infection. It employed a novel approach in that the study design included provider-delivered partner therapy that utilized local pharmacies.
   Google Scholar
• Blythe MJ, Katz BP, Batteiger BE, Ganser JA, Jones RB. Recurrent genitourinary chlamydial infections in sexually active female adolescents. J. Pediatr. 121, 487–493 (1992).
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Andersen B, Moller JK, Olesen F. Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. Clin. Infect. Dis. 31(4), 951–957 (2000).
   Google Scholar
• Dessus-Babus S, Bebear CM, Charron A, Bebear C, De Barbeyrac B. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob. Agents Chemother. 42,2474–2481 (1998).
   Google Scholar
• Dreses-Werringloer U, Padubrin I, Jurgens-Saathoff B, Hudson AP, Zeidler H, Kohler L. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob. Agents Chemother. 44(12), 3288–3297 (2000).
   PubMed Web of Science ®Google Scholar
• Morrissey I, Salman H, Bakker S, Farrell D, Bebear CM, Ridgway G. Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations. J. Antimicrob. Chemother. 49(5), 757–761 (2002).
   PubMed Web of Science ®Google Scholar
• Jones RB, Van der Pol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J. Infect. Dis. 162, 1309–1315 (1990).
   PubMed Web of Science ®Google Scholar
• •Attributes treatment failure to an antimicrobial-resistant Chlamidia trachomatis strain.
   Google Scholar
• Lefevre JC, Lepargneur JP, Guion D, Bei S. Tetracycline-resistant Chlamydia trachomatis in Toulouse, France. Pathol Bid (Paris) 45(5), 376–378 (1997).
   Google Scholar
• •Attributes treatment failure to an antimicrobial-resistant C. trachomatis strain.
   Google Scholar
• Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J. Infict. Dis. 181,1421–1427 (2000).
   PubMed Web of Science ®Google Scholar
• •Attributes treatment failure to an antimicrobial-resistant C trachomatis strain.
   Google Scholar
• Misyurina OY, Chipitsyna EV, Finashutina YP, et al Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides. Antimicrob. Agents Chemother 48(4), 1347–1349 (2004).
   PubMed Web of Science ®Google Scholar
• Bragina EY, Gomberg MA, Dmitriev GA. Electron microscopic evidence of persistent chlamydial infection following treatment. j Eur Acad Dermatol Venervol. 15(5), 405–409 (2001).
   PubMed Web of Science ®Google Scholar
• Thambar IV, Simmons PD, Thin RN, Darougar S, Yearsley P Double-blind comparison of two regimens in the treatment of nongonococcal urethritis. 7-day vs. 21-day course of triple tetracycline. Br J. Vener Dis. 55,284–288 (1979).
   PubMedGoogle Scholar
• Lassus A, Paavonen J, Kousa M, Saikku Erythromycin and lymecycline treatment in Chlamydia-positive and Chlamydia-negative nongonococcal urethritis — a partner-controlled study. Acta Derm. Venerol 59, 278–281 (1979).
   PubMed Web of Science ®Google Scholar
• Pedersen LN, Kjxr HO, Moller JK, Omtoft TF, Ostergaard L. High-resolution genotyping of Chlamydia trachomatis from recurrent urogenital infections. J. Clin. Microbial 38,3068–3071 (2000).
   PubMed Web of Science ®Google Scholar
• Barnes RC, Roddy RE, Stamm WE. Serovars of Chlamydia trachomatis causing repeated genital infection. In: Chlamydial Infections. Oriel D, Ridgway G, Schachter J, Taylor-Robinson D, Ward M (Eds). Cambridge University Press, Cambridge, UK, 503–507 (1986).
   Google Scholar
• Munday PE, Thomas BJ, Gilroy CB, Gilchrist C, Taylor-Robinson D. Infrequent detection of Chlamydia trachomatis in a longitudinal study of women with treated cervical infection. Genitourin. Med 71,24–26 (1995).
   PubMedGoogle Scholar
• Katz BP, Fortenberry D, Orr D. Factors affecting chlamydial persistence or recurrence one and 3 months after treatment. In: Chlamydial Infictions. Proceedings of the Ninth International Symposium on Human Chlamydial Infections. Stephens RS, Byrne GI, Christiansen G, et al (Eds), Berkeley University Press, CA, USA, 35–38 (1998).
   Google Scholar
• Van der Willigen AH, Van Rijsoord-Vos T, Wagenvoort JHT, Stamm WE, Suchland RJ, Stolz E. Antimicrobial susceptibility and serotyping of Chlamydia trachomatis strains isolated before and after treatment with ciprofloxacin and doxycycline. Eur. J. Clin. Microbial Infect. Dis. 11,561–563 (1992).
   PubMed Web of Science ®Google Scholar
• Dean D, Suchland RJ, Stamm WE. Evidence of long-term cervical persistence of C. trachomatis by ompl genotyping. J. Infect. Dis. 182,909–916 (2000).
   PubMed Web of Science ®Google Scholar
• Andersen AA, Rogers KG. Resistance to tetracycline and sulfadiazine in swine C trachomatis isolates. In: Chlamydial Infections. Proceedings of the Ninth International Symposium on Human Chlamydial Infections. Stephens RS, Byrne GI, Christiansen G, et al. (Eds). Berkeley University Press, CA, USA, 313–316 (1998).
   Google Scholar
• Workowski KA, Lampe MF, Wong KG, Watts MB, Stamm WE. Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy. Evidence against persistent infection. J. Am. Med. Assoc. 270(17), 2071–2075 (1993).
   Google Scholar
• Gaydos CA, Crotchfelt KA, Howell MR, Kralian S, Hauptman P, Quinn TC. Molecular amplification assays to detect chlamydial infections in urine specimens from high school female students and to monitor the persistence of chlamydial DNA after therapy. J. Infect. Dis. 177(2), 417–424 (1998).
   PubMed Web of Science ®Google Scholar
• Rothstein DM, Hartman AD, Cynamon MH, Eisenstein BI. Development potential of rifalazil. Expert. Opin. Investig. Drugs. 12(2), 255–271 (2003).
   PubMed Web of Science ®Google Scholar
• Mae T, Konishi E, Hosoe K, Hidaka T Isolation and identification of major metabolites of rifalazil in mouse and human. Xenobiotica 29(11), 1073–1087 (1999).
   PubMed Web of Science ®Google Scholar
• Schachter J, Christiansen G, Clark N, et al. (Eds). Chlamydia trachomatis strains associated with treatment failure or same strain recurrence. In: Chlamydial Infections. Proceedings of the 10th International Symposium on Human Chlamydial Infections. International Chlamydia Symposium, CA, USA, 353–356 (2002).
   Google Scholar
• Gustafsson I, Hjelm E, Cars 0. In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 44(7), 1846–1849 (2000).
   Google Scholar
• Miyashita N, Fukano H, Niki Y, Matsushima T. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J. Antimicrob. Chemother. 48(3), 403–405 (2001).
   Google Scholar
• Dreses-Werringloer U, Padubrin I, Zeidler H, Kohler L. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob. Agents Chemother 45(11), 3001–3008 (2001).
   PubMed Web of Science ®Google Scholar
• Wolf K, Malinvemi R Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis. Antimicrob. Agents Chemother 43(6), 1491–1493 (1999).
   PubMed Web of Science ®Google Scholar